ProQR Therapeutics (PRQR) Accounts Payables (2021 - 2025)

ProQR Therapeutics' Accounts Payables history spans 4 years, with the latest figure at $17097.5 for Q4 2024.

  • For Q4 2024, Accounts Payables fell 98.97% year-over-year to $17097.5; the TTM value through Dec 2024 reached $17097.5, down 98.97%, while the annual FY2024 figure was $17317.4, 98.96% down from the prior year.
  • Accounts Payables for Q4 2024 was $17097.5 at ProQR Therapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.7 million in Q4 2023 and bottomed at $17097.5 in Q4 2024.
  • The 4-year median for Accounts Payables is $309217.7 (2021), against an average of $573389.1.
  • The largest annual shift saw Accounts Payables skyrocketed 314.57% in 2023 before it crashed 98.97% in 2024.
  • A 4-year view of Accounts Payables shows it stood at $218498.5 in 2021, then skyrocketed by 83.04% to $399937.0 in 2022, then soared by 314.57% to $1.7 million in 2023, then plummeted by 98.97% to $17097.5 in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Accounts Payables are $17097.5 (Q4 2024), $1.7 million (Q4 2023), and $399937.0 (Q4 2022).